Kronos Bio, Inc. Stock Price, News & Analysis

Kronos Bio reported progress in its clinical pipeline and financial results for Q4 and full-year 2021. The company continues to enroll patients in the Phase 1/2 trial of the CDK9 inhibitor KB-0742, expecting to announce a recommended Phase 2 dose and updated data in Q4 2022. The Phase 3 AGILITY trial of entospletinib is underway, aiming for results in H2 2023. As of December 31, 2021, Kronos had $339.5 million in cash, expected to fund operations into H2 2024. The company's Q4 net loss was $62.3 million, or $1.13 per share.

Kronos Bio, Inc. (Nasdaq: KRON) announced the appointment of Dr. Elizabeth Olek as senior vice president of Clinical Development, effective February 1, 2022. Dr. Olek, previously at Loxo Oncology, will oversee the planning and execution of clinical trials for the company's investigational drugs, including entospletinib, which is currently in a pivotal Phase 3 AGILITY trial for NPM1-mutated acute myeloid leukemia. The company plans to initiate additional clinical trials this year, enhancing its pipeline focused on cancer therapies.

Kronos Bio, Inc. (Nasdaq: KRON) has initiated the Phase 3 AGILITY clinical trial of entospletinib, targeting acute myeloid leukemia (AML) with the NPM1 mutation. This trial, the first to utilize measurable residual disease (MRD) as its primary endpoint, aims for accelerated FDA approval. Approximately 180 adults will participate, with results anticipated in late 2023. The trial follows a $29 million milestone payment due to Gilead Sciences upon its initiation. If successful, entospletinib could be the first approved treatment for newly diagnosed patients with NPM1-mutated AML.

Kronos Bio, Inc. (Nasdaq: KRON) unveiled positive interim data from its Phase 1/2 trial for KB-0742, a selective CDK9 inhibitor targeting MYC-amplified solid tumors. The trial, ongoing with a three-day on, four-day off schedule, reported a 24-hour terminal half-life for the drug and evidence of dose-dependent target engagement. Out of 12 patients, results showed favorable pharmacokinetics with low-to-moderate patient variability. The next step involves further dose escalation to define a recommended Phase 2 dose, aiming for anti-tumor activity assessment in later stages.

Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company focused on cancer therapies, announced participation in two upcoming investor conferences. Management will engage in fireside chats at Piper Sandler’s 33rd Annual Virtual Healthcare Conference on November 30, 2021, and Evercore ISI’s 4th Annual HealthCONx on December 2, 2021. Both chats will be accessible through the company’s website, with replays available for a month afterward. Kronos Bio specializes in targeting dysregulated transcription factors, with a focus on treatments for acute myeloid leukemia and solid tumors.

Kronos Bio, Inc. (Nasdaq: KRON) announced the appointment of Roshawn Blunt to its Board of Directors. With over 25 years in the biopharmaceutical sector, Blunt is the managing director of 1798, LLC and has held key roles at Amgen and Johnson & Johnson. CEO Norbert Bischofberger expressed confidence in her expertise, particularly in commercialization and patient access, which will support upcoming product launches. Blunt's background includes strategic positions focused on health economics, enhancing Kronos Bio's capacity as it advances investigational products toward market approval.

Kronos Bio reported third-quarter financial results and significant pipeline advancements. The company has $398.4 million in cash as of September 30, 2021, and is set to present interim data from its Phase 1/2 trial of CDK9 inhibitor KB-0742 by year-end. Kronos initiated two new discovery programs targeting MYC and AR transcriptional regulatory networks. Additionally, the FDA cleared its IND for lanraplenib, allowing a Phase 1b/2 trial for AML. R&D expenses were $24.7 million, contributing to a net loss of $33.6 million for the quarter.

Kronos Bio, Inc. (Nasdaq: KRON) and Tempus have announced a multi-year collaboration that enhances Kronos' access to Tempus' genomic and transcriptomic data, vital tools, and analytics. This partnership aims to accelerate the clinical development of Kronos' cancer therapies, such as KB-0742, by utilizing organoid models and virtual cohorts for refined biomarker hypotheses testing. The agreement builds on prior collaborations, including molecular characterization of patient samples in ongoing clinical studies, enhancing the potential for more effective cancer treatments.

Kronos Bio, Inc. (Nasdaq: KRON) announced participation in the BMO Biopharma Spotlight Series on November 8. Charles Lin, Ph.D., Senior Vice President, Biology, will speak on a panel about emerging trends in oncology. A replay will be available on the company’s website for a month. Kronos Bio focuses on developing therapies for cancer, including its lead investigational drug, entospletinib, for NPM1-mutated acute myeloid leukemia, and KB-0742, a treatment for MYC-amplified solid tumors.